VistaGen Therapeutics Reports Positive Results of PH94B in P-III study for Social Anxiety Disorder (SAD)

 VistaGen Therapeutics Reports Positive Results of PH94B in P-III study for Social Anxiety Disorder (SAD)

VistaGen Therapeutics Reports Positive Results of PH94B in P-III study for Social Anxiety Disorder (SAD)

Shots:

  • The P-III study involves assessing of PH94B vs PBO in 22 patients with Social Anxiety Disorder
  • P-III study results: @1wk. decrease in average peak Subjective Units of Distress scores; decrease in Liebowitz Social Anxiety Scale (LSAS) avoidance scores; no Adverse Events; safety profile was excellent; Presented at Anxiety and Depression Association of America Annual Conference 2019
  • PH94B is a neuroactive nasal spray contains pherines involves activation of chemosensory receptors that triggers neural circuits in the brain suppressing fear and anxiety and will be evaluated in P-III development program as an on-demand PRN treatment for SAD

Click here to read full press release/ article | Ref: VistaGen Therapeutics | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post